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Consecutive non-replicate clinical isolates (n=191) 
of carbapenem non-susceptible Enterobacteriaceae 
were collected from 21 hospital laboratories across 
Italy from November 2013 to April 2014 as part of 
the European Survey on Carbapenemase-producing 
Enterobacteriaceae (EuSCAPE) project. Klebsiella pneu-
moniae carbapenemase-producing K. pneumoniae 
(KPC-KP) represented 178 (93%) isolates with 76 (43%) 
respectively resistant to colistin, a key drug for treat-
ing carbapenamase-producing Enterobacteriaceae. 
KPC-KP colistin-resistant isolates were detected in 
all participating laboratories. This underscores a con-
cerning evolution of colistin resistance in a setting of 
high KPC-KP endemicity. 
We report the widespread and rapid dissemination of 
resistance against colistin, a key drug for treatment 
of carbapenamase-producing Enterobacteriaceae, 
among Klebsiella pneumoniae carbapenemase (KPC)-
producing K. pneumoniae (KPC-KP) in Italy. As part of 
the European Survey on Carbapenemase-producing 
Enterobacteriaceae (EuSCAPE) project, consecutive 
non-replicate clinical isolates of carbapenem non-sus-
ceptible (resistant or intermediate) Enterobacteriaceae 
(n=191) were collected from 21 Italian hospital labora-
tories between November 2013 and April 2014. Most 
isolates 178 (93%) were KPC-KP, with 76 (43%) respec-
tively resistant to colistin. This report details the find-
ings and discusses potential implications for infection 
control.
Background
Carbapenem-resistant Enterobacteriaceae (CRE) 
emerged in recent years as one of the most challeng-
ing group of antibiotic-resistant pathogens. Related 
mortality rates are high due to limited treatment 
options, and some strains have the potential for rapid 
dissemination in healthcare settings [1,2]. In Europe, 
CRE have been reported from virtually all countries, 
but in some countries, namely Greece and Italy, they 
have spread rapidly and are presently endemic in 
many hospitals [3,4]. Resistance to carbapenems 
in Enterbacteriaceae is largely due to production of 
enzymes (carbapenemases) inactivating these antibi-
otics, hence the definition of carbapenemase-produc-
ing Enterobacteriaceae (CPE).
In Italy, the dramatic increase of carbapenem-resist-
ant Klebsiella pneumoniae has been documented by 
the European Antimicrobial Resistance Surveillance 
Network (EARS-Net) which showed that the percentage 
of invasive isolates of carbapenem-resistant K. pneu-
moniae, that was until 2009 lower than one to 2%, 
increased to 15% in 2010 to reach 35% in 2013 ([5] and 
unpublished data). Data provided by Micronet (http://
www.simi.iss.it/micronet.htm), a sentinel epidemio-
logical surveillance network based on computerised 
daily collection of microbiological data from the labo-
ratory information systems of 27 laboratories nation-
wide, confirmed the increase in the percentage of 
carbapenem-resistant K. pneumoniae in samples from 
different anatomical sites, including lower respiratory 
secretions and urine [6]. In addition, analysis of resist-
ance determinants and clonality, revealed that the 
Italian CRE epidemic was mostly sustained by KPC-KP 
of clonal complex 258, with only a minority of different 
clones and resistance mechanisms [7].
Polymyxins (colistin and polymyxin B), together with 
tigecycline and gentamicin, are among the few agents 
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that retain activity against KPC-KP, and are key compo-
nents of the combination antimicrobial regimens that 
are recommended for treatment of these pathogens 
[8,9]. Therefore, the emergence of resistance to these 
last line drugs among KPC-KP is important to monitor.
Implementation of European Survey 
on Carbapenemase-producing 
Enterobacteriaceae in Italy
EuSCAPE is funded by the European Centre for Disease 
Prevention and Control (ECDC) and coordinated by the 
Department of Medical Microbiology of the University 
Medical Center Groningen in the Netherlands. This 
initiative aims to foster active surveillance of CPE 
through improving the diagnostic capacity of micro-
biological laboratories in Europe [10]. A crucial part of 
EuSCAPE consisted of a structured survey that between 
November 2013 and April 2014 involved hospital labo-
ratories from 35 countries across Europe. In each par-
ticipating country the National Expert Laboratory (NEL) 
collected and characterised clinical isolates of sus-
pected carbapenem non-susceptible K. pneumoniae 
or Escherichia coli obtained from a sentinel network 
of peripheral laboratories (PLs). Each PL was asked to 
collect the first 10 consecutive non-replicate isolates 
of suspected carbapenem non-susceptible K. pneumo-
niae or E. coli obtained fxrom clinical samples (blood, 
lower respiratory tract secretions, urine, puncture flu-
ids and wound secretions) and to provide also relevant 
demographic and clinical data (age, sex, location of 
patient in hospital, previous hospital admission in the 
last six months, previous stay or travel abroad within 
the last six months).
In Italy, a total of 21 PLs that served 45 hospitals or 
outpatients clinics distributed across the country par-
ticipated in the survey. PLs identified suspected car-
bapenem non-susceptible K. pneumoniae or E. coli by 
automated systems Vitek 2 (bioMérieux, Marcy l’Etoile, 
France) or Phoenix (Becton Dickinson Diagnostic 
Systems, Sparks, MD, USA). Subsequently these iso-
lates were sent to the NEL in Rome, who in collaboration 
with the NEL in Siena, performed confirmation and fur-
ther characterisation. NELs confirmed species identifi-
cation by matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry (Vitek 
MS, bioMérieux), and carried out susceptibility testing 
against carbapenems and other antimicrobial agents 
by reference broth microdilution [11] using commer-
cial microtitre plates (Alere Technologies, GmbH, Jena, 
Germany) and manually prepared plates for colistin 
testing. Results were interpreted according to the 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) clinical breakpoints [12]. The pres-
ence of carbapenemase genes of the blaKPC, blaNDM, 
blaVIM, and blaOXA-48 types was investigated by poly-
merase chain reaction (PCR) using the protocol recom-
mended by EuSCAPE (available upon request from the 
EuSCAPE Coordinator, Prof. Hajo Grundmann).
Results of the survey
A total of 197 suspected carbapenem non-susceptible 
K. pneumoniae or E. coli isolates were collected by 
the PLs in the study period. Of these, 187 K. pneumo-
niae and four E. coli were confirmed as non-suscepti-
ble to at least one carbapenem antibiotic (imipenem, 
meropenem or ertapenem). The blaKPC determinant 
was found to be the most prevalent among carbap-
enem non-susceptible isolates, being detected in 178 
K. pneumoniae and in three E. coli, while other carbap-
enemase genes were infrequently found (Table).
KPC-KP were obtained from urine (67 isolates), blood 
(61 isolates), lower respiratory tract (21 isolates), 
wound secretions (10 isolates), and other specimens 
(19 isolates). Patients with KPC-KP had a median age of 
72 years (range: 16–94 years); 106 (60%) were males 
and 72 (40%) were females. Of these patients, 41(23%) 
had KPC-KP isolates detected while in intensive care 
unit (ICU), 127 (71%) were found while in a medical or 
surgical ward, and 10 (6%) were outpatients or patients 
seen at the emergency department. Another hospital 
admission in the previous six months was reported 
for 96 (64%) of patients for whom the information was 
available (n=150). Travelling abroad during the last six 
months was reported for only 3 (3%) of the patients 
for whom the information was available (n=111). Thus, 
97% (108/111) of KPC-KP infections are endemic cases.
Table
Carbapenemase determinants detected in the confirmed carbapenem non-susceptible isolates collected as part of the 
EuSCAPE survey, Italy, November 2013–April 2014 (n=191)
Species
Number of isolates per type of carbapenemase 
blaKPC blaVIM blaNDM blaOXA-48 None detected
Klebsiella pneumoniae 178a 3 1 1 4
Escherichia colib 3 1 – – –
EuSCAPE: European Survey on Carbapenemase-producing Enterobacteriaceae.
K. pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) were reported from all peripheral laboratories.
a Detected from all the 21 peripheral laboratories.
b The four carbapenemase-producing E. coli isolates were from different peripheral laboratories.
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Antimicrobial susceptibility data for the 178 KPC-KP 
isolates revealed that 76 (43%) were resistant to colis-
tin, 11 (6%) resistant or intermediate to tigecycline, 29 
(16%) resistant or intermediate to gentamicin, and 146 
(82%) resistant or intermediate to trimethoprim-sul-
famethoxazole (SXT). Two isolates (1%) were resistant 
or intermediate to all four antibiotics. Colistin-resistant 
KPC-KP isolates were detected from all PLs, although 
at variable percentages (Figure).
Discussion and conclusions
Although most recent data from April 2014 to date 
are not available at this time, the results of this sur-
vey confirmed the widespread endemicity of KPC-KP in 
Italian healthcare facilities, and their predominant role 
among CPE. Infections with KPC-KP affect mostly older 
patients hospitalised in medical or surgical wards with 
a known history of previous hospital admission in the 
country. The results of this present study also reveal a 
concerning percentage of resistance to colistin, which 
is a matter of major concern given the dearth of treat-
ment options against CPE.
In Italy, the emergence of colistin-resistant KPC-KP has 
been reported since 2010 [13] and, in the first Italian 
nationwide cross-sectional survey on CRE, carried out 
in mid-2011, the overall percentage of colistin resist-
ance among KPC-KP was found to be 22.4%, with 
colistin-resistant isolates reported from 13 of 25 partic-
ipating hospital laboratories [7]. In the EuSCAPE study, 
the colistin resistance percentage found among KPC-KP 
was almost double, and colistin-resistant KPC-KP iso-
lates were detected from all 21 PLs in the study. We 
did not have information to derive the total number of 
affected hospitals among the 45 served by the 21 PLs, 
however the PLs were distributed all across the coun-
try. A similar situation of nationwide dissemination of 
colistin-resistant KPC-KP has not yet been reported in 
other settings of high KPC-KP endemicity [14].
According to data available from the European 
Surveillance of Antimicrobial Consumption Network 
(ESAC-NET) database [15], consumption of polymixins 
in the hospital sector in Italy increased from 0.0017 to 
0.0194 Defined Daily Dose (DDD) per 1,000 inhabitants 
per day in the period from 2007 to 2012. This 10-fold 
increase reflects the increasing dissemination of mul-
tidrug-resistant Gram-negative infections for which 
colistin remains one of the few therapeutic options and 
most likely contributed to selection of colistin-resistant 
strains among KPC-KP.
To control the spread of KPC-KP in Italy, in February 
2013 the Ministry of Health issued a circular letter [16] 
asking the Italian regions to report all cases of blood-
stream infections due to CPE of the species K. pneumo-
niae or E. coli and recommending control measures to 
limit the spread in healthcare settings. These control 
measures consist of: (i) active screening of selected 
patient groups including patients who have been in 
contact with CPE-colonised or infected patients, and 
patients coming from countries with high CPE endemic-
ity and, if feasible, patients admitted to ICU or other 
high-risk wards and patients with a history of previous 
hospitalisation; (ii) isolation or cohorting of infected/
colonised patients, separate cohort nursing care, and 
implementation of contact precautions, according to 
the recommendations issued at national and interna-
tional level [17-20].
These measures require huge efforts and resources in 
an endemic situation like the one highlighted in this 
study, since patients with KPC-KP infection or coloni-
sation are not confined to ICUs, but can be found in 
normal hospital wards. It seems therefore urgent to 
develop and implement a national plan for the preven-
tion and control of CPE infections in Italy that includes 
Figure
Distribution of peripheral laboratories reporting KPC-
producing K. pneumoniae isolates in the EuSCAPE Italian 





















EuSCAPE: European Survey on Carbapenemase-producing 
Enterobacteriaceae; KPC: Klebsiella pneumoniae carbapenemase; 
KPC-KP: KPC-producing K. pneumoniae. 
The peripheral laboratories are numbered on the map according to 
alphabetical order.
Proportions of colistin-resistant isolates among KPC-KP per 
peripheral laboratory:. 1, Alessandria: 1/10; 2, Ancona: 8/10; 3, 
Ferrara: 1/4; 4, Florence: 5/10; 5, Foggia: 4/10; 6, Lecco: 2/9; 7, 
Milan: 1/10; 8, Modena: 3/7; 9, Neaples: 3/8; 10, Perugia: 5/10; 
11, Reggio Calabria: 4/10; 12, Rome: 4/9; 13, Rome: 2/4; 14, Rome: 
6/7; 15, San Remo: 4/8; 16, Siena: 6/8; 17, Treviso: 1/7; 18, Turin: 
5/9; 19, Udine: 2/8; 20, Venice: 8/10; 21, Vercelli: 1/10.
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an extensive surveillance system and more compre-
hensive guidelines on infection control measures. 
Sufficient resources should be allocated to contain the 
further dissemination of CPE in healthcare institutions.
CCHFV was isolated in vitro from the PCR-positive 
serum sample within the Containment Level 4 labora-
tory at PHE Porton, using the human SW13 cell line. 
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